



Immunopharmacology: Developing Immunomodulation and Immunotherapy Strategies for Tumors and Inflammatory Disorders

Guest Editor:

Dr. Naoyoshi Maeda

Center for Research and
Education on Drug Discovery,
Faculty of Pharmaceutical
Sciences, Hokkaido University,
Kita-12, Nishi-6, Kita-ku, Sapporo
060-0812, Japan

Deadline for manuscript
submissions:

closed (31 March 2021)

Message from the Guest Editor

Dear Colleagues,

In this Special Issue of *Vaccines*, we focus on recent immunotherapeutic drug development, covering not only mAbs and its various applications, such as antibody-drug conjugates and single chain fragment variables, but also biologics and chemical compounds that regulate or modulate immune responses, which can also be utilized as vaccines or adjuvants targeting factors in the above diseases. In the area of immunopharmacology, we also hope to discuss strategies for overcoming issues related to adverse effects, leading to the improvement of therapeutic agents. Naturally, we also welcome original articles and reviews covering conventional immunopharmacological studies looking towards identification of novel drug targets and factors, or elucidating their mechanisms of action during immune reactions.

Dr. Naoyoshi Maeda

Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

Journal Rank: JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com